February 1, 2018

GOG-0286B:  " A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer"

NCI Version date: June 21, 2017

GOG-0286B will be permanently closed effective February 1, 2018. Patient follow-up will continue as outlined in the protocol until further notice.

Please visit the GOG-0286B protocol page on the NRG Oncology website protocol table to obtain a copy of the following documents:

-Protocol document reflecting date of closure (0286B page under Protocol Documents)
-Dear Investigator Letter (0286B page under Correspondence & Instructions -- Study Memos)
-Dear Patient Letter (0286B page under Correspondence & Instructions -- Study Memos)

NRG Oncology is proud to be an active participant of #CancerMoonShot.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address